The FDA briefing documents for the November 14 AdCom meeting are a strong positive for Amarin (AMRN). The conclusion was that "the benefit-risk assessment favors the use of Vascepa for CVD risk reduction". Mineral oil was seen as only having a 3% impact on the CVD risk in the worst-case scenario, leaving around 22% RRR attributable to Vascepa.
The only negative appears to be a potential cautionary note about the potential for increased risk of atrial fibrillation/flutter, but that appears most relevant for the 9% of the study population with a prior history